Quarterly ResultMay 11, 2026, 04:14 PM
ArriVent BioPharma Q1 Net Loss $43.3M; Firmonertinib Phase 3 Data Mid-2026
AI Summary
ArriVent BioPharma reported a net loss of $43.3 million for the first quarter ended March 31, 2026, an improvement from $64.4 million in Q1 2025. The company highlighted significant pipeline progress, including expected topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC by mid-2026. Additionally, the Investigational New Drug (IND) application for ARR-002, a dual-targeting ADC, was cleared by the FDA, with plans to dose the first patient in 2H 2026 for ovarian and endometrial cancers. ArriVent also reported $326.4 million in cash and investments, providing a projected cash runway into Q4 2027.
Key Highlights
- Topline global pivotal Phase 3 data for firmonertinib expected mid-2026.
- IND clearance for ARR-002, with first patient dosing planned for 2H 2026.
- Cash and investments totaled $326.4 million as of March 31, 2026.
- Cash runway expected to fund operations into Q4 2027.
- Net loss was $43.3 million for Q1 2026, down from $64.4 million in Q1 2025.
- Research and development expenses decreased to $37.6 million in Q1 2026.
- ARR-217 dosed its first patient in March 2026, advancing Phase 1.
- Firmonertinib received NMPA accelerated approval in China in Feb 2026.